Effectiveness of KOS-862 in the Treatment of Lung Cancer

A Phase 2 Study of KOS-862, Administered Intravenously Weekly for 3 Weeks Every 4 Weeks, in Patients With Non-Small Cell Lung Cancer Who Have Progressed Following Initial Therapy for Advanced or Metastatic Disease

Status

Terminated

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00080509

Enrollment

Registered

2004-04-07

Start date

2003-12-31

Completion date

2004-11-30

Last updated

2010-02-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung Cancer

Brief summary

The purpose of this study is to determine whether a potential drug known as KOS-862 or Epothilone D has an effect as a 2nd line treatment in non-small cell lung cancer (NSCLC) for patients having failed one prior platinum-containing chemotherapy regimen.

Detailed description

To determine the antitumor activity, based on the confirmed objective response rate, of KOS-862, administered intravenously weekly for 3 weeks every 4 weeks, in patients with non-small cell lung cancer (NSCLC) whose disease has progressed following initial chemotherapy for advanced or metastatic disease.

Interventions

DRUGKOS-862

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* At least 18 years of age * Measurable disease * One previous treatment of a platinum based drug such as cisplatin or carboplatin * At least 3 weeks since last surgery/radiation/chemotherapy

Exclusion criteria

* Brain metastases * Changes in the rhythm of your heart that are considered significant as determined by an ECG tracing

Design outcomes

Primary

Measure	Time frame
NSCLC	—

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026